Initiation of intravitreal aflibercept injection treatment in patients with diabetic macular edema: a review of VIVID-DME and VISTA-DME data

[1]  A. Yoshida,et al.  SHORT-TERM EFFECT OF INTRAVITREAL RANIBIZUMAB THERAPY ON MACULAR EDEMA AFTER BRANCH RETINAL VEIN OCCLUSION , 2016, Retina.

[2]  N. Bressler,et al.  Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial. , 2016, Ophthalmology.

[3]  N. Bressler,et al.  Five-Year Outcomes of Ranibizumab With Prompt or Deferred Laser Versus Laser or Triamcinolone Plus Deferred Ranibizumab for Diabetic Macular Edema. , 2016, American journal of ophthalmology.

[4]  Jennifer K. Sun,et al.  Association of Baseline Visual Acuity and Retinal Thickness With 1-Year Efficacy of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema. , 2016, JAMA ophthalmology.

[5]  Q. Nguyen,et al.  Outcomes with As-Needed Ranibizumab after Initial Monthly Therapy: Long-Term Outcomes of the Phase III RIDE and RISE Trials. , 2015, Ophthalmology.

[6]  P. Mitchell,et al.  Three-year patient-reported visual function outcomes in diabetic macular edema managed with ranibizumab: the RESTORE extension study , 2015, Current medical research and opinion.

[7]  P. Kaiser,et al.  Intravitreal Aflibercept for Diabetic Macular Edema: 100-Week Results From the VISTA and VIVID Studies. , 2015, Ophthalmology.

[8]  S. Sivaprasad,et al.  Ranibizumab 0.5 mg for Diabetic Macular Edema with Bimonthly Monitoring after a Phase of Initial Treatment: 18-Month, Multicenter, Phase IIIB RELIGHT Study. , 2015, Ophthalmology.

[9]  S. Wolf,et al.  Prognostic significance of foveal capillary drop-out and previous panretinal photocoagulation for diabetic macular oedema treated with ranibizumab , 2015, British Journal of Ophthalmology.

[10]  A. Koh,et al.  The REVEAL Study: Ranibizumab Monotherapy or Combined with Laser versus Laser Monotherapy in Asian Patients with Diabetic Macular Edema. , 2015, Ophthalmology.

[11]  J. Kleijnen,et al.  Systematic review and mixed treatment comparison of intravitreal aflibercept with other therapies for diabetic macular edema (DME) , 2015, BMC Ophthalmology.

[12]  Jennifer K. Sun,et al.  Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. , 2015, The New England journal of medicine.

[13]  P. Kaiser,et al.  Intravitreal aflibercept for diabetic macular edema. , 2014, Ophthalmology.

[14]  G. Virgili,et al.  Anti-vascular endothelial growth factor for diabetic macular oedema. , 2014, The Cochrane database of systematic reviews.

[15]  G. Lang,et al.  Capacity of aflibercept to counteract VEGF-stimulated abnormal behavior of retinal microvascular endothelial cells. , 2014, Experimental eye research.

[16]  P. Mitchell,et al.  Three-year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema: the RESTORE extension study. , 2014, Ophthalmology.

[17]  A. Cruess,et al.  Contemporary Management of Diabetic Retinopathy in Canada: From Guidelines to Algorithm Guidance , 2013, Ophthalmologica.

[18]  N. Eter,et al.  Stellungnahme der Deutschen Ophthalmologischen Gesellschaft, der Retinologischen Gesellschaft und des Berufsverbandes der Augenärzte Deutschlands: Therapie der diabetischen Makulopathie (Stand April 2013) , 2013, Klin Monatsbl Augenheilkd.

[19]  Benjamin J. Thomas,et al.  Evolving strategies in the management of diabetic macular edema: clinical trials and current management. , 2013, Canadian journal of ophthalmology. Journal canadien d'ophtalmologie.

[20]  Ursula Schmidt-Erfurth,et al.  One-year outcomes of the da Vinci Study of VEGF Trap-Eye in eyes with diabetic macular edema. , 2012, Ophthalmology.

[21]  T. Peto,et al.  A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3. , 2012, Archives of ophthalmology.

[22]  P. Mitchell,et al.  New approaches for the treatment of diabetic macular oedema: recommendations by an expert panel , 2012, Eye.

[23]  L. Aiello,et al.  Rationale for the diabetic retinopathy clinical research network treatment protocol for center-involved diabetic macular edema. , 2011, Ophthalmology.

[24]  E. Halm,et al.  Predictors of adherence to diabetes medications: the role of disease and medication beliefs , 2009, Journal of Behavioral Medicine.

[25]  Judy E. Kim,et al.  Comparison of Aflibercept, Bevacizumab, and Ranibizumab for Treatment of Diabetic Macular Edema: Extrapolation of Data to Clinical Practice. , 2016, JAMA ophthalmology.

[26]  N. Eter,et al.  [Statement of the German Ophthalmological Society, the Retina Society and the Professional Association of German Ophthalmologists: treatment of diabetic maculopathy (April 2013)]. , 2013, Klinische Monatsblatter fur Augenheilkunde.